跳至主要内容
临床试验/CTRI/2024/04/066232
CTRI/2024/04/066232尚未招募3 期

A Randomized, Open Label Trial to Compare Efficacy and Safety of Olanzapine 10mgand 5mg for the prophylaxis of emesis in patients receiving highly emetogenic cancer chemotherapy - nil

Department of Pharmacology and Department of RadioOncology0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1-18 years of age or older patients who had not received previous chemotherapy
  • 2-Patients going to receive 1st cycle of highly emetogenic cancer chemotherapy
  • 3-Written informed consent.
  • 4-Able to understand and describe patient-reported outcomes.

排除标准

  • 1-History of hypersensitivity or allergy to any of antiemetic drugs we are going to use in study
  • 2-Received any chemotherapy in last 3 weeks.
  • 3-Multiday chemotherapy regimen, concurrent radiotherapy
  • 4-brain metastasis

研究者

发起方
Department of Pharmacology and Department of RadioOncology

相似试验